131 research outputs found

    Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY registry

    Get PDF

    Plaque athéromateuse instable. Physiopathologie et approche thérapeutique de I'insuffisance coronaire

    No full text
    SCOPUS: ar.jinfo:eu-repo/semantics/publishe

    Rôle du tonus coronaire vasomoteur dans l'angor chronique stable :aspects cliniques et pharmacologiques

    No full text
    Doctorat en sciences pharmaceutiquesinfo:eu-repo/semantics/nonPublishe

    Unstable atherosclerotic plaque. Pathophysiology and therapeutic guidelines

    No full text
    SCOPUS: ar.jinfo:eu-repo/semantics/publishe

    Bradykinin and the therapeutic actions of angiotensin-converting enzyme inhibitors

    No full text
    SCOPUS: ar.jinfo:eu-repo/semantics/publishe

    L'endothelium vasculaire: Organe cible des pathologies cardio- vasculaires

    No full text
    SCOPUS: cp.jinfo:eu-repo/semantics/publishe

    Rôle du tonus coronaire vasomoteur dans l'angor chronique stable :aspects cliniques et pharmacologiques

    No full text
    Doctorat en sciences pharmaceutiquesinfo:eu-repo/semantics/nonPublishe

    Revascularization versus medical treatments in stable coronary artery disease: Predicting the future of novel drug therapies for stable angina

    No full text
    ABSTRACT: Over the past 2 decades, drug therapy of patients with stable angina pectoris has improved, with a marked impact on the hard clinical outcomes of mortality and myocardial infarction. In contrast, recent trials have not demonstrated beneficial effects of revascularization on mortality. However, in the large trials that compared medical treatment with percutaneous coronary intervention (PCI) or surgery, high-risk patients, such as those with severe 3-vessel disease with or without left ventricular dysfunction, were excluded. In the COURAGE and FAME 2 trials, the only difference between the PCI and medical therapy groups was a higher rate of revascularization in the latter. Similar findings were made in studies comparing medical treatment with coronary surgery. New pharmacological approaches are being developed to further delay the progression of atherosclerosis. These include new lipid-lowering drugs acting in concert with statins (cholesteryl ester transfer protein inhibitors, proprotein convertase subtilisin/kexin type 9 inhibitors), aldosterone antagonists, colchicine, methotrexate, and interleukin-1 inhibitors. In conclusion, from the available data, PCI and coronary surgery have not been shown to improve hard end points and routine use of invasive revascularization should be avoided in patients with chronic stable angina. Evidence-based secondary prevention remains the most important approach. Copyright © 2013 by Lippincott Williams & Wilkins.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

    Alpha-adrenergic coronary constriction in effort angina.

    No full text
    SCOPUS: ar.jinfo:eu-repo/semantics/publishe

    Persistence of the response to SIN1 on isolated coronary arteries rendered tolerant to nitroglycerin in vitro or in vivo

    No full text
    Experiments were performed on isolated canine and human coronary arteries to provide more insight into the mechanisms responsible for the vascular tolerance to nitroglycerin that is induced under in vitro or in vivo conditions. In vitro tolerance was produced after an incubation of coronary ring segments with nitroglycerin (10 μM for 30 min at physiological pH). After elevation of tone with KCl (15 mM), dose-response curves were constructed for nitroglycerin or SIN1 (3-morpholino-syndonimin) on control and tolerant rings. On canine tolerant rings the dose-response curve for nitroglycerin-induced relaxations was significantly (p < 0.001) shifted to the right, and 50% of the maximal relaxation (ED50) increased from 55 ± 9 nM to 1.2 ± 0.2 μM. Pretreatment of tolerant rings with N-acetylcysteine (NAC, 10 μM 10 min before KCl-induced contraction) partially restored the responsiveness to nitroglycerin, with ED50 reducing to 0.56 ± 0.03 μM (p < 0.02). O)n the other hand, the dose-response curves to SIN1 were not significantly altered. Similar results were obtained on human preparations. On isolated canine coronary rings rendered tolerant in vivo by subcutaneous injections of 15 mg/kg nitroglycerin (two times daily for 4 consecutive days), ED50 for nitroglycerin was 0.67 ± 0.08 μM (p < 0.001 versus control rings), and NAC again partially restored the reponsiveness to nitroglycerin. As for the in vitro tolerance, the relaxations to SIN1 were not significantly altered on these canine rings rendered nitrate tolerant in vivo. The present results show that the responsiveness to SIN1 is not modified on nitrate tolerant rings and that the mechanisms responsible for nitrate tolerance are similar under both in vivo and in vitro conditions.SCOPUS: NotDefined.jinfo:eu-repo/semantics/publishe
    corecore